Trump said to be improving but next 48 hours ‘critical’

[Image]( EMAIL}/redirect By JONATHAN LEMIRE, JILL COLVIN and ZEKE MILLER BETHESDA, Md. (AP) — President Donald Trump went through a “very concerning” period Friday and faces a “critical” next two days in his fight against COVID-19 at a military hospital, his chief of staff said Saturday — in contrast to a rosier assessment moments earlier by Trump doctors, who took pains not to reveal the president had received supplemental oxygen at the White House before his hospital admission. “We’re still not on a clear path yet to a full recovery,” White House chief of staff Mark Meadows said outside the Walter Reed National Military Medical Center. The changing, and at times contradictory accounts, created a credibility crisis for the White House at a crucial moment, with the president’s health and the nation’s leadership on the line. With Trump expected to remain hospitalized several more days and the presidential election looming, his condition is being anxiously watched by Americans. EMAIL}/redirect EMAIL}/redirect Moreover, the president’s health represents a national security issue of paramount importance not only to the functions of the U.S. government but to countries around the world, friendly and otherwise. Saturday’s briefing by Navy Commander Dr. Sean Conley and other doctors raised more questions than it answered. Conley repeatedly refused to say whether the president ever needed supplemental oxygen, despite repeated questioning, and declined to share key details including how high a fever Trump had been running before it came back down to a normal range. Conley also revealed that Trump had begun exhibiting “clinical indications” of COVID-19 on Thursday afternoon, earlier than previously known. Conley spent much of the briefing dodging reporters’ questions, as he was pressed for details. “Thursday no oxygen. None at this moment. And yesterday with the team, while we were all here, he was not on oxygen,” Conley said. But according to a person familiar with Trump’s condition, Trump was administered oxygen at the White House on Friday morning, well before he was transported to the military hospital by helicopter that evening. The person was not authorized to speak publicly and spoke to The Associated Press only on condition of anonymity, Conley said that Trump’s symptoms, including a mild cough, nasal congestion and fatigue “are now resolving and improving,” and said the president had been fever-free for 24 hours. But Trump also is taking aspirin, which lowers body temperature and could mask or mitigate that symptom. EMAIL}/redirect EMAIL}/redirect “He’s in exceptionally good spirits,” said another doctor, Sean Dooley, who said Trump’s heart, kidney, and liver functions were normal and that he was not having trouble breathing or walking around. Trump is 74 years old and clinically obese, putting him at higher risk of serious complications from a virus that has infected more than 7 million people nationwide and killed more than 200,000 people in the U.S. Meadows himself had insisted Friday morning that Trump had only “mild symptoms” as the White House tried to project an image of normalcy. It was unclear whether Trump already had received oxygen when Meadows spoke. “President Trump remains in good spirits, has mild symptoms and has been working throughout the day,” press secretary Kayleigh McEnany said late in the day on Friday. She said Trump had only been sent to Walter Reed as a precaution. Trump’s administration has been less than transparent with the public throughout the pandemic, both about the president’s health and the virus’ spread inside the White House. The first word that a close aide to Trump had been infected came from the media, not the White House. And aides have repeatedly declined to share basic health information, including a full accounting of the president’s symptoms, what tests he’s undertaken and the results. In a memo released late Friday, Conley did report that Trump had been treated at the hospital with remdesivir, an antiviral medication, after sharing that he’d taking another experimental drug at the White House. Conley declined to say when Trump had last been tested before he was confirmed to have COVID-19 late Thursday. He initially suggested that Trump was 72 hours into the diagnosis — which would mean that he was confirmed infected Wednesday. Conley later clarified that Trump was administered an accurate test for the virus on Thursday afternoon, after White House aide Hope Hicks was confirmed to be positive and Trump exhibited “clinical indications” of the virus. The White House has said Trump was expected to stay at the hospital for “a few days” and would continue to work from its presidential suite, which is equipped to allow him to keep up his official duties. In addition to accessibility to tests and equipment, the decision to move to the hospital on Friday was made, at least in part, with the understanding that hurrying there later could send a worrying signal if he took a turn for the worse. On Saturday, Conley said Trump’s blood oxygen level was 96%, which is in the normal range. The two experimental drugs he has received, given through an IV, have shown some promise against COVID-19. On Friday, he was given a single dose of a drug Regeneron Pharmaceuticals Inc. is testing to supply antibodies to help his immune system fight the virus. Friday night, he began a five-day course of remdesivir, a Gilead Sciences drug currently used for moderately and severely ill patients. The drugs work in different ways — the antibodies help the immune system rid the body of virus and remdesivir curbs the virus’ ability to multiply. “We’re maximizing all aspects of his care,” attacking the virus in multiple ways, Conley said. “I didn’t want to hold anything back if there was any possibility it would add value to his care.” He noted that in many cases, COVID-19 can become more dangerous as the body responds. “The first week of COVID, and in particular day seven to 10, are the most critical in determining the likely course of this illness,” he said. At the same time, the White House has been working to trace a flurry of new infections of close Trump aides and allies. Attention is focused in particular on last Saturday’s White House event introducing Trump’s Supreme Court nominee. That day, Trump gathered more than 150 people in the Rose Garden, where they mingled, hugged and shook hands — overwhelmingly without masks. There were also several indoor receptions, where Trump’s Supreme Court pick, Judge Amy Coney Barrett, her family, senators and others spent time in the close quarters of the White House, photographs show. Among those who attended and have now tested positive: former New Jersey Gov. Chris Christie, White House counselor Kellyanne Conway, the president of the University of Notre Dame, and at least two Republican lawmakers — Utah Sen. Mike Lee and North Carolina Sen. Thom Tillis. The president’s campaign manager, Bill Stepien, and the head of the Republican National Committee, Ronna McDaniel, have also tested positive, though they were not at the event. Despite its failure to protect the president and senior staff from infection, the White House has given no indication that it intends to make any major protocol changes, such as mandating that everyone wears a mask. Meadows, the chief of staff, accompanied the president to the hospital aboard Marine One, the kind of small, enclosed space where experts say the virus easily spreads. Those aboard did wear masks. While Vice President Mike Pence is currently off the campaign trail preparing for the coming week’s vice presidential debate, he and his staff are operating under a “business as usual” approach. He’s still planning to travel to Arizona on Thursday, Indiana on Friday and Florida on Saturday for events instead of isolating himself after potential exposure and to protect himself from contracting the virus anywhere else. __ Colvin and Miller reported from Washington. Associated Press chief medical writer Marilynn Marchione contributed to this report from Milwaukee. EMAIL}/redirect EMAIL}/redirect © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has not been compensated for this specific email, we do have advertisements in this email that we get paid if you click one of the ads (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](